Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction
Academic Article
Publication Date:
2013
Abstract:
Human stresscopin is a corticotropin-releasing factor (CRF) type 2 receptor (CRFR2) selective agonist and a member of the CRF peptide family. Stimulation of CRFR2 improves cardiac output and left ventricular ejection fraction (LVEF) in patients with stable heart failure (HF) with reduced LVEF. We examined the safety, pharmacokinetics, and effects on haemodynamics and serum biomarkers of intravenous human stresscopin acetate (JNJ-39588146) in patients with stable HF with LVEF ≤ 35% and cardiac index (CI) ≤ 2.5 L/min/m(2).
CRIS type:
1.1 Articolo in rivista
Keywords:
Corticotropin-releasing factor type 2 receptor; Haemodynamics; Heart failure; Human stresscopin; Pharmacokinetics; Adult; Aged; Biological Markers; Blood Pressure; Cardiac Output; Corticotropin-Releasing Hormone; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Failure; Heart Rate; Hemodynamics; Humans; Infusions, Intravenous; Male; Middle Aged; Pulmonary Wedge Pressure; Stroke Volume; Urocortins
List of contributors:
Gheorghiade, Mihai; Greene, Stephen J; Ponikowski, Piotr; Maggioni, Aldo P; Korewicki, Jerzy; Macarie, Cezar; Metra, Marco; Grzybowski, Jacek; Bubenek Turconi, Serban Ion; Radziszewski, Waldemar; Olson, Allan; Bueno, Orlando F; Ghosh, Atalanta; Deckelbaum, Lawrence I; Li, Lilian Y; Patel, Ayan R; Koester, Andreas; Konstam, Marvin A.
Published in: